Sunday, October 19, 2025 9:19:35 PM
zero82,
Thanks for continually reposting your free pearls of wisdom 😶
Intense interest & commitment are always impressive & notable! NWBO has sparked some interest… really makes ya think…
Thanks for highlighting “big pharma” again—it’s a fascinating topic…
The checkpoint inhibitor Opdivo (Nivolumab)
made by Bristol Myers Squibb was slated to be studied at UCLA in combo with DCVax-L, but the contract negotiations did not work out and the study was withdrawn. But there is an ongoing study at UCLA with Merck’s checkpoint inhibitor Keytruda (pembrolizumab)…
✅️ Merck’s pembrolizumab is being studied in combo with multiple DC platforms licensed to NWBO, and Dr. Kalinski recently cited MTA agreements with Merck.
Below is one very noteworthy example of DC vaccine in combo with TLR & PD1 blockade. We will see what comes next. There are multiple TLR agonist agents, multiple checkpoint inhibitors, and NWBO has in-licensed multiple dendritic cell platforms. Partnership(s) & collaborations announcements could include any of the companies that make TLR agonists or checkpoint inhibitors.
clinicaltraials.gov NCT04201873
Bullish Insight
NWBO to Acquire Advent BioServices
Thanks for continually reposting your free pearls of wisdom 😶
Intense interest & commitment are always impressive & notable! NWBO has sparked some interest… really makes ya think…
Thanks for highlighting “big pharma” again—it’s a fascinating topic…
The checkpoint inhibitor Opdivo (Nivolumab)
made by Bristol Myers Squibb was slated to be studied at UCLA in combo with DCVax-L, but the contract negotiations did not work out and the study was withdrawn. But there is an ongoing study at UCLA with Merck’s checkpoint inhibitor Keytruda (pembrolizumab)…
✅️ Merck’s pembrolizumab is being studied in combo with multiple DC platforms licensed to NWBO, and Dr. Kalinski recently cited MTA agreements with Merck.
Below is one very noteworthy example of DC vaccine in combo with TLR & PD1 blockade. We will see what comes next. There are multiple TLR agonist agents, multiple checkpoint inhibitors, and NWBO has in-licensed multiple dendritic cell platforms. Partnership(s) & collaborations announcements could include any of the companies that make TLR agonists or checkpoint inhibitors.
clinicaltraials.gov NCT04201873
Bullish Insight
NWBO to Acquire Advent BioServices
Bullish
Believe carefully. This is the greatest and most powerful lesson that I have learned since arriving on Earth. Examine what you believe about yourself most importantly, and then believe carefully as you interact with the world.
Recent NWBO News
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 04/16/2026 09:25:30 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 04/07/2026 04:30:50 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 03/31/2026 09:04:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/15/2026 10:06:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/02/2026 10:14:59 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 11/28/2025 09:43:27 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 11/26/2025 05:15:34 AM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 11/25/2025 10:23:07 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/20/2025 09:26:03 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 11/19/2025 09:15:48 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:44:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2025 04:29:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/30/2025 08:40:05 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/24/2025 04:28:38 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/14/2025 06:22:26 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/14/2025 09:00:38 PM
- Form 424B5 - Prospectus [Rule 424(b)(5)] • Edgar (US Regulatory) • 07/01/2025 09:04:38 PM
